SCHEMBL2201365

SCHEMBL2201365

CCOC(=O)c1c(C)c(-c2cccc(Br)c2)nn1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1F O60840 1/20 0.47
ABCB1 P08183 1/20 0.47
CACNA1D Q01668 1/20 0.47
CACNA1S Q13698 1/20 0.47
CACNA1C Q13936 1/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
ELANE P08246 3/20 0.45
CYP19A1 P11511 2/20 0.44
ALOX5 P09917 3/20 0.43
FOS P01100 1/20 0.43
JUN P05412 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
PTGES O14684 1/20 0.43
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2202998 0.83 ALDH1A1 (0.44) NPC1RAB9AALDH1A1KDM4ENPSR1
SCHEMBL2201905 0.81 CYP19A1 (0.52) CACNA1FABCB1CACNA1DCACNA1SCACNA1C
SCHEMBL5023330 0.77 SLC34A1 (0.49) NPC1RAB9AELANEALDH1A1KDM4E
SCHEMBL4489852 0.77 FAAH (0.57) NPC1RAB9AELANECYP19A1ALOX5
SCHEMBL4496559 0.77 FAAH (0.57) CACNA1FABCB1CACNA1DCACNA1SCACNA1C
SCHEMBL6225292 0.74 KDM4E (0.57) KDM4E
SCHEMBL10960761 0.74 LMNA (0.41) ELANEALDH1A1GAAMAPTNPSR1
SCHEMBL2200016 0.72 JAK1 (0.41) ALDH1A1PLAU
SCHEMBL29627840 0.72 KDM4E (0.65) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL245137 0.72 KDM4E (0.65) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
EP-2182953-A2 NEW PYRAZOL DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-12 EP disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 CACNA1F 2060/4885ABCB1 257/4885CACNA1D 2029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.